Microprose Inc.This Hunt Valley-based entertainment...

BY THE NUMBERS

November 08, 1991

Microprose Inc.

This Hunt Valley-based entertainment software developer reported net income of $811,000, or 16 cents a share, for the quarter that ended Sept. 30. In the year-earlier period, Microprose reported net income of $310,000, or 7 cents a share. Microprose, which completed its initial public offering last month, said that international and domestic sales of its computer games remained strong.

Three months ended 9/30/91

.. .. Revenue.. .. Net.. .. .. Share

'91.. $9,204,000.. $811,000 ..0.16

'90.. $6,686,000.. $310,000 ..0.07

% change.. +37.7.. ..+161.6 .. +128.6

Six months ended 6/30/91

.. .. Revenue.. .. Net.. .. .. Share

'91.. 15,855,000..902,000. ..0.18

'90..11,386,000..(211,000)..(0.04)

% change.. +39.2.. .. .. -- .. --

MedImmune Inc.

The Gaithersburg biotechnology company said that it eked out a small profit during the third quarter and announced a 2.5 million share stock offering.

"These results are consistent with our expectations and reflect our commitment to profitable growth from the development of our therapeutic and vaccine products," President Wayne T. Hockmeyer said. "However, quarter-to-quarter financial results may vary significantly, due to the timing of product deliveries, milestone payments and the pace of research and development activities."

About half of the company's $2.4 million in revenues could be attributed to CytoGam, an immunotherapeutic drug used to treat infections linked to certain viruses that can weaken the immune system.

The company said that 2 million of the 2.5 million shares to be offered will be sold by venture capital funds that own a stake in MedImmune. The other 500,000 shares will be sold by the company; the estimated $25 million in revenues from those shares will be used for research, working capital, facility expansion and general corporate purposes.

Three months ended 9/30/91

.. .. ..Revenue.. .. Net.. .. .. Share

'91.. ..$2,400,000.. $100,000 ..0.00

'90.. ..$500,000. .. $(1,200,000)(0.27)

% change+380.0 .. .. -- .. .. .. --

Nine months ended 9/30/91

.. .. .. Revenue.. .. Net.. .. .. Share

'91.. .. $10,400,000. $1,600,000.0.11

'90.. .. $1,800,000.. (2,500,000) (0.61)

% change +477.8 .. .. -- .. .. .. --

Genetic Therapy Inc.

This Gaithersburg-based biotech firm said that it posted an expected third-quarter loss in its first quarterly report as a public company.

Genetic Therapy, which went public in July at $9 a share, said that it lost $1.27 million, or 19 cents a share, on revenue of about $133,000. But the company's announcement stressed the progress it has made in its research programs.

"Our research and development programs are proceeding on schedule, with several new protocols initiated or approved," said M. James Barrett, GTI's chief executive officer. In October, GTI signed a research and development agreement with the National Institutes of Health related to lung diseases.

GTI completed its initial public offering as an over-the-counter stock July 31. The offering yielded net proceeds of $12,325,000. The stock closed yesterday at $20 a share.

Three months ended 9/30/91

.. .. .. Revenue.. .. Net.. .. .. .. Share

'91.. .. $133,373. .. $(1,270,000).. (0.19)

'90.. .. $22,640.. .. $(911,122). ..(0.16)

% change +489.1 .. .. -39.4 18.7. .. -

Nine months ended 9/30/91

.. .. .. Revenue.. .. Net.. .. .. .. Share

'91.. .. $256,352. .. $(3,500,000)..(0.57)

'90.. .. $140,458. .. $(2,800,000)..(0.49)

% change +82.5. .. .. -25.0.. .. .. -16.3

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.